Session

Overview: Oligometastatic disease in prostate cancer has become an emerging situation that we are facing more frequently, mainly due to the incorporation of the new generation of molecular imaging both, in the initial staging of high-risk patients and in the biochemical failure setting, together with increasing availability of high-precision technology in radiotherapy treatments. Specifically, stereotaxic body/ablative radiotherapy (SBRT-SABR) has gained popularity because of a low profile of described complications, an excellent tolerability and a reduced treatment time which is very convenient for patients and departments. This session will cover the available evidence supporting SBRT for oligometastases, including the biological, observational and randomized data, the real impact on clinical outcome, and the controversial, still non-resolved issues.